853 related articles for article (PubMed ID: 24411404)
1. Outcome measures for primary Sjögren's syndrome: a comprehensive review.
Seror R; Theander E; Bootsma H; Bowman SJ; Tzioufas A; Gottenberg JE; Ramos-Casals M; Dörner T; Ravaud P; Mariette X; Vitali C
J Autoimmun; 2014 Jun; 51():51-6. PubMed ID: 24411404
[TBL] [Abstract][Full Text] [Related]
2. Outcome measures for primary Sjögren's syndrome.
Seror R; Bootsma H; Bowman SJ; Dörner T; Gottenberg JE; Mariette X; Ramos-Casals M; Ravaud P; Theander E; Tzioufas A; Vitali C
J Autoimmun; 2012 Aug; 39(1-2):97-102. PubMed ID: 22365784
[TBL] [Abstract][Full Text] [Related]
3. European League Against Rheumatism Sjögren's Syndrome Disease Activity Index and European League Against Rheumatism Sjögren's Syndrome Patient-Reported Index: a complete picture of primary Sjögren's syndrome patients.
Seror R; Gottenberg JE; Devauchelle-Pensec V; Dubost JJ; Le Guern V; Hayem G; Fauchais AL; Goeb V; Hachulla E; Hatron PY; Larroche C; Morel J; Pedriger A; Puechal X; Rist S; Saraux A; Sene D; Sibilia J; Vittecoq O; Zarnitsky C; Labetoulle M; Ravaud P; Mariette X
Arthritis Care Res (Hoboken); 2013 Aug; 65(8):1358-64. PubMed ID: 23436737
[TBL] [Abstract][Full Text] [Related]
4. Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI).
Seror R; Theander E; Brun JG; Ramos-Casals M; Valim V; Dörner T; Bootsma H; Tzioufas A; Solans-Laqué R; Mandl T; Gottenberg JE; Hachulla E; Sivils KL; Ng WF; Fauchais AL; Bombardieri S; Valesini G; Bartoloni E; Saraux A; Tomsic M; Sumida T; Nishiyama S; Caporali R; Kruize AA; Vollenweider C; Ravaud P; Vitali C; Mariette X; Bowman SJ;
Ann Rheum Dis; 2015 May; 74(5):859-66. PubMed ID: 24442883
[TBL] [Abstract][Full Text] [Related]
5. EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren's syndrome.
Seror R; Ravaud P; Mariette X; Bootsma H; Theander E; Hansen A; Ramos-Casals M; Dörner T; Bombardieri S; Hachulla E; Brun JG; Kruize AA; Praprotnik S; Tomsic M; Gottenberg JE; Devauchelle V; Devita S; Vollenweider C; Mandl T; Tzioufas A; Carsons S; Saraux A; Sutcliffe N; Vitali C; Bowman SJ;
Ann Rheum Dis; 2011 Jun; 70(6):968-72. PubMed ID: 21345815
[TBL] [Abstract][Full Text] [Related]
6. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren's syndrome treated with rituximab.
Meiners PM; Arends S; Brouwer E; Spijkervet FK; Vissink A; Bootsma H
Ann Rheum Dis; 2012 Aug; 71(8):1297-302. PubMed ID: 22258489
[TBL] [Abstract][Full Text] [Related]
7. Severe Health-Related Quality of Life Impairment in Active Primary Sjögren's Syndrome and Patient-Reported Outcomes: Data From a Large Therapeutic Trial.
Cornec D; Devauchelle-Pensec V; Mariette X; Jousse-Joulin S; Berthelot JM; Perdriger A; Puéchal X; Le Guern V; Sibilia J; Gottenberg JE; Chiche L; Hachulla E; Yves Hatron P; Goeb V; Hayem G; Morel J; Zarnitsky C; Dubost JJ; Saliou P; Pers JO; Seror R; Saraux A
Arthritis Care Res (Hoboken); 2017 Apr; 69(4):528-535. PubMed ID: 27390310
[TBL] [Abstract][Full Text] [Related]
8. The EULAR Sjogren's syndrome patient reported index as an independent determinant of health-related quality of life in primary Sjogren's syndrome patients: in comparison with non-Sjogren's sicca patients.
Cho HJ; Yoo JJ; Yun CY; Kang EH; Lee HJ; Hyon JY; Song YW; Lee YJ
Rheumatology (Oxford); 2013 Dec; 52(12):2208-17. PubMed ID: 24023247
[TBL] [Abstract][Full Text] [Related]
9. Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI).
Seror R; Bootsma H; Saraux A; Bowman SJ; Theander E; Brun JG; Baron G; Le Guern V; Devauchelle-Pensec V; Ramos-Casals M; Valim V; Dörner T; Tzioufas A; Gottenberg JE; Solans Laqué R; Mandl T; Hachulla E; Sivils KL; Ng WF; Fauchais AL; Bombardieri S; Priori R; Bartoloni E; Goeb V; Praprotnik S; Sumida T; Nishiyama S; Caporali R; Kruize AA; Vollenweider C; Ravaud P; Meiners P; Brito-Zerón P; Vitali C; Mariette X;
Ann Rheum Dis; 2016 Feb; 75(2):382-9. PubMed ID: 25480887
[TBL] [Abstract][Full Text] [Related]
10. Assessment of fatigue and dryness in primary Sjögren's syndrome: Brazilian version of "Profile of Fatigue and Discomfort - Sicca Symptoms Inventory (short form) (PROFAD-SSI-SF)".
Miyamoto ST; Paganotti MA; Serrano ÉV; Giovelli RA; Valim V
Rev Bras Reumatol; 2015; 55(2):113-22. PubMed ID: 25582994
[TBL] [Abstract][Full Text] [Related]
11. How to assess treatment efficacy in Sjögren's syndrome?
Vissink A; Bootsma H; Kroese FG; Kallenberg CG
Curr Opin Rheumatol; 2012 May; 24(3):281-9. PubMed ID: 22450393
[TBL] [Abstract][Full Text] [Related]
12. Clinimetric methods in Sjögren's syndrome.
Hernández-Molina G; Sánchez-Hernández T
Semin Arthritis Rheum; 2013 Jun; 42(6):627-39. PubMed ID: 23352255
[TBL] [Abstract][Full Text] [Related]
13. Systemic involvement in primary Sjogren's syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients (GEAS-SS Registry).
Ramos-Casals M; Brito-Zerón P; Solans R; Camps MT; Casanovas A; Sopeña B; Díaz-López B; Rascón FJ; Qanneta R; Fraile G; Pérez-Alvarez R; Callejas JL; Ripoll M; Pinilla B; Akasbi M; Fonseca E; Canora J; Nadal ME; de la Red G; Fernández-Regal I; Jiménez-Heredia I; Bosch JA; Ayala MD; Morera-Morales L; Maure B; Mera A; Ramentol M; Retamozo S; Kostov B; ;
Rheumatology (Oxford); 2014 Feb; 53(2):321-31. PubMed ID: 24162151
[TBL] [Abstract][Full Text] [Related]
14. Sjögren's Systemic Clinical Activity Index (SCAI)--a systemic disease activity measure for use in clinical trials in primary Sjögren's syndrome.
Bowman SJ; Sutcliffe N; Isenberg DA; Goldblatt F; Adler M; Price E; Canavan A; Hamburger J; Richards A; Rauz S; Regan M; Gadsby K; Rigby S; Jones A; Mathew R; Mulherin D; Stevenson A; Nightingale P
Rheumatology (Oxford); 2007 Dec; 46(12):1845-51. PubMed ID: 18032543
[TBL] [Abstract][Full Text] [Related]
15. The Sjögren's Syndrome Damage Index--a damage index for use in clinical trials and observational studies in primary Sjögren's syndrome.
Barry RJ; Sutcliffe N; Isenberg DA; Price E; Goldblatt F; Adler M; Canavan A; Hamburger J; Richards A; Regan M; Gadsby K; Rigby S; Jones A; Mathew R; Mulherin D; Stevenson A; Nightingale P; Rauz S; Bowman SJ
Rheumatology (Oxford); 2008 Aug; 47(8):1193-8. PubMed ID: 18524804
[TBL] [Abstract][Full Text] [Related]
16. Baseline disease activity influences subsequent achievement of patient acceptable symptom state in Sjögren's syndrome.
Park EH; Ha YJ; Kang EH; Song YW; Scofield RH; Lee YJ
Rheumatology (Oxford); 2021 Jun; 60(6):2714-2724. PubMed ID: 33188390
[TBL] [Abstract][Full Text] [Related]
17. Transcultural adaptation of the "EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI)" into Brazilian Portuguese.
Serrano EV; Valim V; Miyamoto ST; Giovelli RA; Paganotti MA; Cadê NV
Rev Bras Reumatol; 2013; 53(6):483-93. PubMed ID: 24477727
[TBL] [Abstract][Full Text] [Related]
18. Disease activity and patient reported outcome measures in Sjögren's - what are the best tools to evaluate?
Seror R; Rauz S; Gosset M; Bowman SJ
Rheumatology (Oxford); 2021 Aug; 60(8):3528-3539. PubMed ID: 31236580
[TBL] [Abstract][Full Text] [Related]
19. ESSPRI and other patient-reported indices in patients with primary Sjogren's syndrome during 100 consecutive outpatient visits at one rheumatological clinic.
Pertovaara M; Korpela M
Rheumatology (Oxford); 2014 May; 53(5):927-31. PubMed ID: 24464708
[TBL] [Abstract][Full Text] [Related]
20. Advances in the understanding and treatment of systemic complications in Sjögren's syndrome.
Brito-Zerón P; Ramos-Casals M;
Curr Opin Rheumatol; 2014 Sep; 26(5):520-7. PubMed ID: 25050925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
